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The mucosa is part of the first line of immune defense against pathogen exposure in humans and prevents viral and bacterial
infection of the soft palate, lungs, uvula, and nasal cavity that comprise the ear-nose-throat (ENT) region. Bactericidal/permeability-
increasing fold containing family A, member 1 (BPIFA1) is a secretory protein found in human upper aerodigestive tract mucosa.
This innate material is secreted in mucosal fluid or found in submucosal tissue in the human soft palate, lung, uvula, and nasal
cavity. BPIFA1 is a critical component of the innate immune response that prevents upper airway diseases. This review will provide
a brief introduction of the roles of BPIFA1 in the upper airway (with a focus on the nasal cavity, sinus, and middle ear), specifically
its history, identification, distribution in various human tissues, function, and diagnostic value in various upper airway infectious
diseases.
1. Introduction
The gene of the short palate, lung, and nasal epithelium clone
1 (splunc1), now referred to as BPIFA1, was first described
in the palate and nasal epithelium of murine embryonic
and adult lung tissue, which is referred to as plunk [1].
The human gene that encodes BPIFA1 contains nine exons
that are located on chromosome 20q11.2, and its expression
is limited to the upper airway and nasopharyngeal region,
including the trachea and nasal epithelium [2, 3]. Di and
his colleagues [4] determined that this gene, referred to
as spurt (secretory protein in upper respiratory tract), was
significantly induced by all-trans-retinoic acid in primary
cultured human tracheobronchial epithelia.
BPIFA1 is a member of a family of seven proteins that
are encoded by adjacent genes in an approximately 300 kb
region of chromosome 20q11 (Figure 1). The human BPIFA1
cDNA is 1,020 bp in length and contains a leucine-rich
protein of 256 amino acids weighing approximately 25 kDa
[2]. BPIFA1 is also a member of the parotid secretory protein
(PSP)/lipopolysaccharide-binding protein (LBP) superfamily
of proteins [5]. Members of the PLUNC family fall into
two groups based on their size: “short” proteins, a group
comprising BPIFA1 (256 amino acids), SPLUNC2 (249 amino
acids) and SPLUNC3 (253 amino acids) and “long” proteins
comprising LPLUNC1 (484 amino acids), LPLUNC2 (458
amino acids), LPLUNC3 (463 amino acids), and LPLUNC4
(>469 amino acids) [6]. LPLUNC6/BPIFB6 is important in
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Figure 1: The genomic location of BPIFA1 and related BPI family members. BPIFA1 is located on chromosome 20q11.2 and contains nine
exons. There are 7 BPIF gene families located in loci of BPIFA1, BPIFA2, BPIFA3, BPIFB1, BPIFB2, BPIFB3, and BPIFB4.
some virus replication as coxsackievirus B (CVB), poliovirus
(PV), and enterovirus 71 (EV71) [7].
SPLUNC proteins contain domains structurally simi-
lar to the N-terminal domain of bactericidal/permeability-
increasing protein (BPI), whereas LPLUNC proteins contain
domains structurally similar to both domains of BPI [6, 8].
Human BPIFA1 is expressed in the salivary gland, and
nose of the upper respiratory tract [21]. High expression of
BPIFA1 is also found in normal adult nasopharyngeal
epithelium [2, 6, 22], trachea, bronchi of the adult
lung [1, 23]. Various reports have demonstrated that
bactericidal/permeability-increasing fold containing family
A, member 1 (BPIFA1) is present in the innate immune
material that protects against various diseases and has been
widely reported in humans to play a role in lower airway
defense against different kinds of bacterial infection. For
example, higher levels of BPIFA1 have been correlated
with the presence of Pseudomonas pneumonia [16, 24, 25],
Klebsiella pneumonia [26],Mycoplasma pneumonia [27], and
Staphylococcus aureus [28]. BPIFA1 also plays an important
role in the innate immunity of the pulmonary airway against
influenza A [20, 29] and respiratory syncytial virus infection
[14]. Other lower respiratory tract diseases, notably cystic
fibrosis, have also demonstrated a correlation between
BPIFA1 expression and disease progression [21, 30]. Several
reports illustrated a correlation between BPIFA1 expression
and middle ear infection [31], chronic rhinosinusitis
with nasal polyps (CRSwNP) [32, 33], and sinusitis [34].
Quantitation of BPIFA1 expression could be applied as a
diagnostic tool for certain upper airway diseases and may
have a value for determining treatment outcomes. Although
existing reviews have examined the functions of BPIFA1 and
correlations with lower airway diseases, few studies have
focused on its functions and correlates in the upper airway.
2. BPIFA1 Expression and Regulation
After searching the databases, the BPIFA1 in various upper
airway infectious diseases WAS retrieved. Overall, BPIFA1
has been examined through specific expression in upper
airway tracts, including the tongue, tonsil, nasal polyps,
adenoid, and middle ear (Figure 2).
The materials that affect BPIFA1 expression were sum-
marized to assess future therapeutic applications of this
secretory protein in treating upper airway-related diseases
(Table 1). Although there are currently no regimens for
direct supplementation with BPIFA1, repression of BPIFA1
in patients may still be prevented by controlling or treating
the patient’s underlying allergic rhinitis or asthma-related
disease.This approachmay decrease levels of IL-13, a cytokine
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Table 1: Materials that affect BPIFA1 expression.
Effector of BPIFA1
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Nascal cavity: Nasal polyps,
CRSwNP, CRSnNP, allergic 
rhinitis (lowering BPIFA1 
expression)
Oral cavity: Dental caries,
gingivitis (lowering BPIFA1 
expression)
Middle ear: Infection, effusion 
(lowering BPIFA1 expression)
Figure 2: Highly specific expression of BPIFA1 in the human upper airway respiratory system. The major expressed tissues of BPIFA1
are located in the tongue, tonsil, nasal polyps, adenoid, and middle ear (as shown in the left panel). Those lowering BPIFA1 expression are
affected by infections and correlated diseases of upper airway tracts (as shown in the right panel).
secreted by many cell types, primarily Th2 helper T cells, to
help mediate anti-inflammatory responses to allergens and
prevent downregulation of BPIFA1 through the JNK/c-Jun,
API, and ERK pathways.
Another critical protein, lactoferrin, has been shown to
recover expression of BPIFA1 after LPS-induced infection
and is a safe, established product utilized in the treatment of
various human diseases [18]. Lactoferrin is a key innatemate-
rial that defends humans from respiratory syncytial virus,
middle ear infections, and sinusitis, while LPS is an endotoxin
present in the outer membrane of Gram-negative bacteria
that is strongly immunogenic in animals. Supplementation
with lactoferrin has been shown to indirectly recover BPIFA1
attenuated by LPS through downregulation of the MEK/ERK
pathway, suggesting a possible therapeutic benefit for patients
with lower expression of BPIFA1 caused by chronic bacterial
infection. Multiple studies have noted that intranasal steroids
could restore BPIFA1 to normal levels by reactivating AP-1,
the transcription factor responsible for regulating expression
of BPIFA1 [35, 36].
Matrix metalloproteinases (MMPs) are responsible for
degradation of extracellular matrix (ECM) proteins in nor-
mal cell turnover and are upregulated in inflammatory
diseases of oral tissues [37], as well as in dental caries and
oral cancer [38]. It is hypothesized that elevated MMPs may
inhibit the function of BPIFA1.Therefore, inflammation itself
could be the reason for downregulation of BPIFA1. Reducing
inflammation of the nasal epithelium is another strategy to
protect BPIFA1 from inhibition mediated by infection or
injury.
How these studies were executed and their materials
and methods are shown in Table 2 [9, 11–13, 15, 17–19, 39].
Furthermore, Table 3 summarizes the working mechanisms
utilized by BPIFA1 to protect humans from related pathogens,
viral or bacterial, that infect the upper airway. The primary
mode of defense induced by BPIFA1 entails neutralization of
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Table 2: Summary of available BPIFA1 studies, methods of analysis utilized, and related upper airway diseases under study.
Author (year)/[Reference] Study design Material Methods Correlated upper airwaydiseases




Tsou et al. (2015)/[10] Human(in vitro)
Septum squamous
carcinoma
Western blot, RT-PCR, IHC for





Bingle and Gorr (2004)/[11] Human(in vitro)
Human oral, nasal and
respiratory epithelia




Yeh et al. (2010)/[12] Human(in vitro)







Fornander et al. (2013)/[13] Human(in vivo) Nasal lavage fluids
Western blot, 2D gel
electrophoresis Upper airway symptoms
Fornander et al. (2011)/[14] Human(in vivo) Naspharyngeal aspiration




Ghafouri et al. (2006)/[15] Human(in vivo) Nasal lavage fluids









Tsou et al. (2014)/[17] Human(in vivo) Sinus polyps Bacterial culture, RT-PCR, IHC
Sinonasal infections,
CRSWNP
Tsou et al. (2017)/[18] Human(in vitro) Nasal RPMI-2650 cells
Western blot, indirect
immunofluorescence, confocal





Rye et al. (2012)/[19] Human(in vivo)
Genomic DNA was
extracted from blood Single nucleotide polymorphisms Otitis media
Teran et al. (2012)/[20] Human(in vivo) Nasal aspirates
2D gel electrophoresis and mass
spectrometry Seasonal influenza A virus
LPS by direct binding or action as a surfactant to increase
macrophage or neutrophil recruitment to the infected area
of the upper airway. These mechanisms are discussed in the
following sections.
3. Upper Airway Infection and Diseases
Upper airway infections cover a wide disease spectrum in
human history from flu virus pandemics to outbreaks of vari-
ous bacterial infections such as tonsillitis, adenoiditis, sinusi-
tis, pharyngitis, and laryngitis. If not properly controlled or
treated, these conditions may be life-threatening. Among
infections in the head and neck region, tonsillitis, adenoiditis,
and chronic sinusitis are often the most difficult to cure, and
they incur major medical costs around the world in both
adult and pediatric groups [40]. Various antibiotic-resistant
conditions make the diseases hard to treat and susceptible
to relapse in current practice due to both the increased
population of various penicillin-resistant strains [10] and the
intractable condition caused by biofilm accumulation [41].
Therefore, curative surgical procedures such as tonsillectomy
and adenoidectomy (T/A) [42], middle ear surgery, and sinus
surgery are inevitable and are widely used for chronic or
recurrent upper respiratory tract infection (URTI) in child
and adult chronic upper airway infection-related diseases.
Avoidable surgical treatment options are for patients who
have failed to respond to medication, and they are strongly
correlated with tissue biofilm formation that subsequently
elicits lower BPIFA1 production [16, 17]. Some upper airway
infectious diseases such as chronic rhinosinusitis and middle
ear infection lead to biofilm formation and lower BPIFA1
expression and require avoidable surgeries.These pathologies
are summarized below.
3.1. Middle Ear Infection. Current evidence of the direct
relationship between middle ear infection and BPIFA1 is
lacking. Middle ear effusion, or otitis media, has been shown
to exhibit BPIFA1 gene expression [19, 43]. The indirect
relationship of otitismedia andBPIFA1may be related to poor
eustachian tube function and BPIFA1 expression. Patients
with decreased BPIFA1 expression were also noted to be
smokers and to present with allergic rhinitis, conditions
BioMed Research International 5
Table 3: Summary of mechanisms, correlated pathogens, and findings from studies of BPIFA1 and related upper airway diseases.
Author (year)/[Reference] Mechanism Pathogen Findings
Casado et al. (2005)/[9]
Innate immune response in




LC-ESI-MS/MS was involved in acquired
and innate immune response in the nose
against microbial infections and unclean
inhaled air, e.g., rhinosinusitis












IL-13 attenuated LPS (GNB)
bacteria-induced BPIFA1 expression
causing compromise of certain GNB
bacterial infections
Bingle and Gorr (2004)/[11] LPS neutralization Not mentioned
PLUNC proteins mediate host defense
functions in the oral, nasal and
respiratory epithelia
Yeh et al. (2010)/[12] Inhibition of BPIFA1production Not mentioned
IL-13 is harmful to the host innate
immune response through the inhibition
of BPIFA1 production
Fornander et al. (2013)/[13]







IL-1b was significantly higher in subjects
with airway symptoms
Fornander et al. (2011)/[14] Innate immune response Respiratory syncytial virus
A decrease in BPIFA1 in the upper
airways may increase the risk for severe
pneumonia
Ghafouri et al. (2006)/[15]
NLF levels of the cysteine
proteinase inhibitors,
cystatin S and VEGP were
decreased and failed to
inhibit proteinase action in
SAR
Pollen
BPIFA1 is significantly decreased in the
NLF during nasal inflammation by
allergic rhinitis
Tsou et al. (2013)/[16] Anti-bacteria or surfactant Pseudomonas aeruginosa
Sinusitis with bacterial culture positive
for P. aeruginosa isassociated with lower
expression of BPIFA1 and unfavorable
sinus surgery outcomes






BPIFA1 is a novel predictive outcome
biomarker for patients with CRSwNP and
bacterial colonization
Lower BPIFA1 related to multiple
bacterial infections







Lactoferrin could be a possible treatment
strategy for LPS-induced chronic
rhinosinusitis
Rye et al. (2012)/[19]
Genome-wide associated
study of childhood otitis
media susceptibility found
that decreased BPIFA1 was
correlated with higher otitis
media in children
Not mentioned GWAS was performed to identify thegenetic determinants of OM in childhood
Teran et al. (2012)/[20]
Lipocalin-1 can enhance




Seasonal influenza A virus
To provide the pathogenesis of
respiratory infections caused by seasonal
influenza A virus in nasal fluid
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which were shown to increase the risk of developing otitis
media with related middle ear diseases. This decrease in
BPIFA1 expression in sinus or upper airwaymucosa also leads
to repeated infection of the upper airway, including middle
ear infection and sinusitis [44].
3.2. Sinusitis. Chronic rhinosinusitis comprises a notable
portion of upper airway infections and is considered a
chronic upper airway infectious disease with diffuse sinus
mucosa inflammation. In a case control study, the level of
expression of BPIFA1 was depressed in patients with chronic
rhinosinusitis, and the protein was considered to have pro-
vided a protective function in the sinus mucosa [34]. It
was found that sinusitis positive for Pseudomonas aeruginosa
bacterial culture is associated with decreased BPIFA1 in the
sinus mucosa, which may serve as a diagnostic tool to assess
expression of BPIFA1 in patients [16]. Furthermore, BPIFA1
expression was found to be significantly reduced in the
mucosal epithelia and submucosal glands in patients with
multibacterial colonization, particularly those mediated by
Staphylococcus aureus and Pseudomonas aeruginosa [17].
3.3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
Patients with chronic rhinosinusitis with nasal polyps
(CRSwNP) were found to have lower levels of BPIFA1
expression, which was associated with bacterial colonization
[16]. This evidence indicated that decreased levels of BPIFA1
might facilitate bacterial infection in a host, leading to severe
disease manifestations. Repeated sinus surgery is correlated
with lower BPIFA1 expression and subsequently elevated
pseudomonas infection rates. This pattern of repeated surg-
eries in the sinuses as well as poor surgical outcomes is
often observed in CRSwNP [16]. Patients with CRSwNP had
higher secretion of interleukin-13 (IL-13), which appears to
play a critical role in downregulating BPIFA1 expression.
In nasal epithelial cells, IL-13 attenuates BPIFA1 expression
by downregulating the lipopolysaccharide- (LPS-) induced
activation of phosphorylated JNK and c-Jun [39].
CRSwNP is a disorder characterized by a higher trend of
developingTh2-driven inflammation and tissue eosinophilia
that may be induced by microbial infection [45]. IL-13, a
cytokine predominately secreted by Th2, has been found
to contribute to airway allergies and to suppress BPIFA1
expression in nasal epithelial cells [12].
3.4. Allergic Rhinitis. TheBPIFA1 level was significantly lower
in patients with persistent allergic rhinitis (AR) [15, 46]. It was
reported that patients with allergic rhinitis had significantly
higher chronic rhinosinusitis rates than patients without
allergic rhinitis [47]. Patients with lower BPIFA1 expression
were found to be more susceptible to sinus infection by cer-
tain bacterial infection, whichmay explain this phenomenon.
4. Mechanisms and Therapeutic
Use of BPIFA1
4.1. Possible Mechanisms of Defense Function. Several studies
have shown that BPIFA1 possesses antimicrobial activity
and exhibits the same surfactant properties as airway secre-
tions, a trait that may inhibit the formation of bacterial
biofilm. It has also been reported that BPIFA1 plays an
important role in the regulation of airway surface liquid
(ASL) volume [48]. Mechanistically, BPIFA1 contributes to
the innate immune response by directly binding to LPS and
yielding a bactericidal or bacteriostatic effect against various
bacterial infections, an anti-biofilm function, and surfactant
properties. Furthermore, BPIFA1 has been shown to be
secreted from chemoattracted neutrophils or macrophages
to support innate mucosal immunity in the lower airway
[25, 49]. It was also reported that BPIFA1 protein bind-
ing to bacterial lipopolysaccharide inhibited the growth of
Pseudomonas aeruginosa [50], Klebsiella pneumonia [26],
Mycoplasma pneumonia [27], and the Gram-positive bacteria
Staphylococcus areus [28] by its antimicrobial and surfactant
adjusting function.
4.2. Mechanism as Surfactant. The surfactant function of
BPIFA1 has been well-characterized in vitro. BPIFA1 contains
hydrophobic residues and is a pH-sensitive regulator that
can specifically bind to the epithelial Na+ channel (ENaC)
[48]. This channel has been shown to be critical to the
regulation of ASL and absorption of fluids in many epithelia
and is frequently the rate-limiting factor. In addition, BPIFA1
has been hypothesized to act as volume sensors to inhibit
ENaC and thus fluid reabsorption by preventing its cleavage
and activation by serine proteases. This mechanism inhibits
ENaC-dependent Na+ absorption, resulting in preservation
of airway surface liquid volume. A proteomics screen for
molecules that bind trypsin-sensitive ENaC channels iden-
tified BPIFA1 as a candidate volume sensor, which was
supported by subsequent RNA interference (RNAi) knock-
down experiments that demonstrated an inability to regulate
ENaC-mediated fluid reabsorption in bronchial epithelial
cell cultures [51]. Furthermore, the addition of recombinant
BPIFA1 to culture restored ASL volume and ENaC regulation
to normal values. Cells coexpressing cystic fibrosis trans-
membrane conductance regulator (CFTR) and ENaC were
incubated with rBPIFA1, which inhibited ENaC activity but
did not affect CFTR [52]. This illustrates the specificity of
ENaC inhibition by BPIFA1 and its subsequent restoration of
ASL, demonstrating a key molecular mechanism underlying
the increase in mucosal fluid secretion by elevated BPIFA1 in
response to pathogen exposure.
4.3. Relation of LPS Interaction. Possible biochemical path-
ways giving rise to anti-pseudomonas and anti-influenza
infection may be mapped by surveying elevated chemokines
quantitated in BAL and lower airway cell lines or animal
lower airway infection models such as higher levels of
CXCL1, CXCL2, andCCL20 [50]. CXCL1 recruits neutrophils
to the infection site, while CXCL2 recruits monocytes,
macrophages, and granulocytes to combat microbial infec-
tion by innate immune response. BPIFA1 was found to
have an immunomodulatory function through the toll-like
receptor 2 (TLR2) pathway [53], which is responsible for
recognition of pathogens and recruitment of innate immune
cells such as those delineated above. Further, this same review




















Figure 3: Proposed mechanism of IL-13 inhibition of LPS-induced BPIFA1 expression in nasal polyps and adenoid tissue. The IL-13
inhibits BPIFA1 (SPLUNC1) gene expression through a JNK/c-Jun regulation pathway. Lactoferrin also interacts with BPIFA1 in the nasal
polyps and adenoid tissues to avoid LPS-induced inflammation via downregulated MEK1/2-MAPK signaling.
illustrated that downregulation of TLR2 in non-transformed
human bronchial epithelial cells through shRNA interference
reduced BPIFA1 expression, demonstrating a positive corre-
lation between the activation of this pathway and secretion
of BPIFA1 in innate immune material. It was shown that,
in defending the lower airway against Mycoplasma pneu-
monia infection, BPIFA1 signaled through the TLR2-NF-𝜅B
pathway and also throughTLR2-induced (MARK)/activating
protein 1 (AP-1) in human lung epithelium cells [54]. In a
recent survey using a nasal epithelium (RPMI-2650)model, it
was demonstrated that BPIFA1 expression was elevated after
LPS-induced inflammation though the MEK/ERK pathway,
and BPIFA1 expression was attenuated by IL-13 through the
JNK and c-Jun signaling pathway [39] as shown in Figure 3.
Lactoferrin was shown to recover the suppressed BPIFA1
through downregulation of the MEK1/2-MAPK signaling
pathway by preventing BPIFA1 degradation by LPS. However,
whether BPIFA1 exactly could bind with LPS is still ques-
tioned till now, since there was also a study which revealed
that the LPS is not cognate ligand of BPIFA1 [55]. Besides,
we will not just get the concept that BPIFA1 has a similar
structure of BPI, which is a major LPS receptor. Actually,
there is an allergen called dust mite Der P7 having a similar
structure [56]. Therefore, we shall not only just focus on BPI
but also check other ligand binding proteins in future studies.
4.4. Immune Effects. Neutrophil function was enhanced in
the anti-Mycoplasma pneumonia immune response induced
by BPIFA1 in chronic lung disease [27]. In the lower air-
way, knockout BPIFA1 mice were shown to have decreased
mucociliary clearance and decreased innate immune func-
tion [50]. However, this same region in human patients
contains human neutrophilic elastase (HNE), which could
potentially degrade BPIFA1 in chronic obstructive pul-
monary disease (COPD) patients with acute exacerbation of
symptoms by nontypeable Haemophilus influenzae infection
[57]. The mechanism of anti-influenza A function has yet to
be elucidated, but it has been shown that increased amounts
of BPIFA1 were quantitated after lung and bronchoalveolar
lavage (BAL) administration [58]. The protein has been
shown to function as an immunomodulatory material in
the lower airway, as demonstrated in chronic obstructive
pulmonary disease, cystic fibrosis, and idiopathic pulmonary
fibrosis. The expression of human BPIFA1 was altered in
nasal lavage fluids (NLFs) after exposure to irritants and was
quantitated in an increased proportion in NLFs of smokers,
suggesting that it is involved in the airway inflammatory
response [59, 60].
4.5. Microbial Defense. BPIFA1 was also shown to confer a
resistance to Klebsiella pneumonia infection through its abil-
ity to adjust mucosa surface tension in contrast to the BPIFA1
knockout mouse model [26] and to decrease Mycoplasma
pneumoniae levels that subsequently inhibited epithelial IL-
8 production induced by Mycoplasma pneumoniae-derived
lipoproteins. High levels of BPIFA1 have been shown to
be expressed in normal human and mouse large airway
epithelial cells. Although Mycoplasma pneumoniae infection
increases BPIFA1, IL-13 still decreases BPIFA1 expression and
Mycoplasma pneumoniae clearance, suggesting that BPIFA1
serves as a novel host defense protein against Mycoplasma
pneumonia [23].
4.6. Different Mechanisms and Functions of BPIFA1 between
Upper Airway and Lower Airway Infections. The major
pathogens present in the lower airway respiratory tract
include Klebsiella pneumonia, Pseudomonas aeruginosa, and
Mycoplasma pneumonia, while the population of infectious
pathogens in the upper airway includes Staphylococcus
aureus, Pseudomonas aeruginosa, and Klebsiella pneumonia.
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Most of the Gram-negative bacilla (GNB) are correlated with
LPS toxin-induced infections. BPIFA1 has been shown to
neutralize the aforementioned bacterial species in LPS related
interaction reported in the lower and upper airways; however,
whether BPIFA1 binds to LPS is still questioned [18, 61].
The surfactant function of BPIFA1 is demonstrated
mainly in cystic fibrosis in the lower airway and is not widely
reported in the mucosa of the upper airway. Furthermore,
LPS-inducedBPIFA1 expression in the upper airway ismainly
involved in JNK/c-Jun [39] andMEK1/2-MARKpathway sig-
naling [18], while the lower airway ismediated byMARK/AP-
1 activation through the TLR2 pathway [54].The lower airway
attracted neutrophils andmacrophages that could also secrete
BPIFA1 and aid in innate immune protection of pulmonary
tissue, a phenomenon that has not been reported in the upper
airway.
Patients presenting with nasal allergies and Th2-
predominant upper airway allergic rhinitis had higher IL-13
expression correlated with low BPIFA1 expression and high
sinusitis infection rate than patients lacking a background
with allergic rhinitis. This observation also explained a trend
in eosinophilic CRS patients who demonstrated higher IL-13
levels and reduced innate immunity to multiple bacterial,
and specifically pseudomonas, infections compared to
noneosinophilic CRS patients. This pattern was reported in
the lower airway inMycoplasma pneumonia clearance related
to asthma pathobiology [23].
4.7. Materials or Cytokines That Affect BPIFA1 Expression.
IL-13 inhibits BPIFA1 expression in upper airway infection.
Lactoferrin may recover suppressed BPIFA1 expression by
antagonizing LPS and could serve as a future treatment
material in nasal spray treatment or sinus irrigation during
postoperative care (Table 1).
5. Conclusions
The focus of this article was the secretory protein, BPIFA1,
which plays a key role in the regulation of airway surface
liquid volume and serves in host defense against bacterial
infection. BPIFA1 expression was shown to be significantly
reduced in the mucosal epithelia and submucosal glands in
patients with multibacterial colonization, particularly those
mediated by S. aureus and P. aeruginosa, a trend that may
serve as a useful diagnostic marker should methods of
BPIFA1 upregulation or supplementation be adapted for
therapeutic use. CRSwNP patients requiring repeated sinus
surgeries for recurrent or persistent sinusitis also presented
much lower BPIFA1 expression than those who did not
require repeated sinus surgery. Downregulation of BPIFA1
was shown to produce an immune defect that rendered the
host more susceptible to bacterial infection, thus indicating
that reduced SPLUNC1 expression might facilitate recurrent
Staphylococcus aureus and Pseudomonas aeruginosa infec-
tions in patients with CRSwNP. It was demonstrated that IL-
13 plays a critical role in the regulation of BPIFA1 expression
in patients by downregulating the LPS-induced activation of
phosphorylated JNK and c-Jun, followed by attenuation of
BPIFA1 expression in these patients.
Lactoferrin was shown to decrease LPS-induced
inflammation-related protein MEK1/2 and p42/44 MAPK
activation under BPIFA1 recovery. This finding might
suggest that a new therapy could be developed that utilizes
lactoferrin treatment to lessen inflammation and increase
immune response in persistent infection of host airways.
It was noted that patients who underwent surgical pro-
cedures of T/A did not decrease chronic or recurrent upper
respiratory tract infection and that repeated bacterial infec-
tions in the adenoid were shown to be caused by antibiotic
resistance. Furthermore, it was demonstrated that biofilm
formation played a major role in these ENT infections. In
addition, the colonies of S. aureus and P. aeruginosa were
associated with respiratory diseases, chronic adenoiditis,
and rhinosinusitis. Further insight into the mechanism of
biofilm resistance raises a useful future direction in infectious
diseases and postoperative treatment.
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